Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Open Orphan Plc LSE:ORPH London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 2.08% 24.50 24.00 25.00 24.75 23.75 24.00 2,577,686 09:34:57
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.3 -5.6 -3.4 - 164

Open Orphan Share Discussion Threads

Showing 9876 to 9900 of 12200 messages
Chat Pages: Latest  404  403  402  401  400  399  398  397  396  395  394  393  Older
DateSubjectAuthorDiscuss
24/11/2020
14:50
I think because we have been told we have these vaccines, a lot of people have just moved on from covid, they think its a slam dunk. Timetable has already changed and change it will again IMHO. Testing will still be required for a long time and covid is not going away, that is generally accepted. I see "green shares" flavour of the day, are on the move today and gold shares have fallen back. I have topped up on a few as when the reality of this pandemic truly hits home, people will once again be looking for a safe place for their money. Another reason why I like ORPH. CF sees its huge growth potential or I am 100% sure he would have been off, sack full of money, derisked, and onto the next.
m5
24/11/2020
14:41
https://www.youtube.com/watch?v=n7IbXS1nbH0&feature=push-u-sub&attr_tag=HtpXx3xQgZBpQ9Hu%3A6
toyin
24/11/2020
14:32
I wonder if orph is suffering from some sort of aim condition. The sort of thing where rampers say the one in a million chance is a certainty? So many reading this think that covid challenge studies going ahead is a one in a million punt? That would explain the price stall over the last couple of weeks. If that is so, then i wonder if there'll be an aim type boost when the covid model is complete and the covid studies start? That thinking is pretty cack really, since covid is a small part of hvivo, although it has big contracts next year. And multi-million deposits have been paid. And the covid model dev is costing the gov £10m. And the gov have arranged free facilities in the royal free for the studies. And the gov are desperate to boost the flimsy evidence so far on the vaccine candidates by any means possible. Not one in a million imv, more like 99.5% certain.
pierre oreilly
24/11/2020
14:22
Pierre, not sure warranty meant 'ever again', Warranty, must say the thought had crossed my mind wrt the 3 vaccines in the news. All the talk of them being manufactured, shipped and used by Dec clearly indicates that the challenge study is not going to take place prior to first use, if at all and we do not have any confirmation that any or all of these vaccines will undergo a CHIM either prior to or post first use. That is not the same as saying there is no longer a need for CHIMs and the business is dead in the water!! Maybe this question could be addressed to CF at the next video presentation?
lazarus2010
24/11/2020
14:18
Would this help warranty. Flu challenge studies have been ongoing since the early 1940s. They've had flu vaccines since 1945 (thanks to challenge studies in the couple of years before, incidentally done by deptartments now subsumed by and part of hvivo). Flu challenge studies are still on going today.
pierre oreilly
24/11/2020
14:15
I know it all sounds ramptastic!! We know nothing is 100%,and everybody should make their own decisions and do their own research, but I do keep looking for a downside to this and I am struggling. I think CF saw the same, pretty early doors, and that's why he is going on for the ride and to extract maximum value. I think he is pretty ruthless underneath it all, if he felt it wasn't worth his while, in a big way, he would have been onto the next. IMHO.
m5
24/11/2020
14:12
lol! What a time for me to pop up! 8595 wasn't there when i started writing 8596
pierre oreilly
24/11/2020
14:10
Warranty, really mate, the questions you ask are sort of non-questions. It just seems to show a lack of following of everything challenge studies, orph, vaccines, authorisations and everything surrounding the area is about. You seem to assume with 3 vaccines (let's assume they all get approved) challenge studies are not necessary. Or at the very least you must think there's a possibility they're no longer necessary. I honestly can't think how or why you could think having 3 vaccines renders callenge studies, or even covid challenge studies, unnecessary. Even if 140 vaccine candidates get approved, hvivo will still be fully booked and turning away challenge studies for the foreseeable future. I just don't see how you can link a successful covid vaccine to no more challenge studies (or even no more covid challenge studies). The world isn't going to stop once there's a covid vaccine. Soz i can't answer better. If you could say why you think there's a link it may help to answer better.
pierre oreilly
24/11/2020
14:01
m5 you me and Pierre say the same things all the time on this share, very worrying lol
pogue
24/11/2020
13:57
Warranty read the link toyin has put up, as should others, it proves how much testing will be required going forward of vaccines that might actually work.
pogue
24/11/2020
13:53
You beat me to it pogue. Its all there if you listen.
m5
24/11/2020
13:48
warranty listen to the presentation from Thursday from Proactive.
pogue
24/11/2020
13:37
https://www.forbes.com/sites/williamhaseltine/2020/09/23/covid-19-vaccine-protocols-reveal-that-trials-are-designed-to-succeed/?sh=7ea82e405247
toyin
24/11/2020
13:34
Right, don’t shoot me down for this or accuse of decamping or negativity because I’m fully invested and behind Orph and this is a genuine question. is there a possibility that even after paying a deposit for COVID CHIMs, the government pulls out and leans on the regulator to reject our authorisation due to the fact there are now 3 confirmed vaccines? These vaccines have been delivered in months through normal, but hastened testing and without the potential dangers to life and wellbeing of actually infecting volunteers with the virus through CHIMs, even a reduced dose? Secondly, will volunteers now still be willing to take part knowing a vaccine has now been found? I fully accept that Orph isn’t just a COVID play but I suspect the share price has risen mainly due to that despite the additional opportunities from Immutex and wearables?
warranty
24/11/2020
13:13
Sorry forget that link.
m5
24/11/2020
13:08
bramble13, thank you, I certainly will.
m5
24/11/2020
12:48
Surprised at the selling to be honest
judijudi
24/11/2020
12:41
M5 please do an in depth research on Ergomed. You will never regret in. You you wanted a company as good as ORPh ,there's one for you.
bramble13
24/11/2020
12:36
M5...an other excellent pharma company is ergomed ERGO
bramble13
24/11/2020
11:47
Oxford Covid vaccine - Prof Pollard - HIC Vac - ORPH Professer Andrew Pollard is the lead for the Oxford Astra Covid vaccine: https://twitter.com/BBCNews/status/1330954133424238602 He is also the director of the HIC Vac network that aims to accelerate the development of vaccines globally utilising CHIM’s: hxxps://www.hic-vac.org/ ORPH’s recent RNS confirm’s collaboration with HicVac: https://www.londonstockexchange.com/news-article/ORPH/collaboration-with-hic-vac-and-wellcome-trust/14761432 Based on the above, I would guess an Oxford vaccine CHIM study, would be highly likely in the New Year. This would be great kudos for ORPH and likely to generate more head to head CHIM’s in the future. IMHO
trader_3
24/11/2020
11:10
Oxford Covid vaccine hit 90% success rate thanks to dosing error https://www.theguardian.com/uk-news/2020/nov/23/oxford-covid-vaccine-hit-90-success-rate-thanks-to-dosing-error?CMP=Share_iOSApp_Other If a 90% success rate was achieved by a ‘dosing error’, how valuable would a human challenge trial be, in establishing correct dosages and timings for all the new Covid vaccines?
trader_3
24/11/2020
10:58
Still think we are being hit with the covid stick here. We know covid IS not going away and I see rollout has been put back to April/Easter, what a shocker-NOT. What is the betting it goes further back? Blatant BS, but I get why they did it. As we have said before golden opportunity for fresh investors to climb onboard if they can be bothered to do an hours research. What did CF say?, this area has been vastly underfunded for 30 years? Money know being thrown at it and guess who is right at the top of the tree for testing. It's not rocket science is it? Then we have the non core stuff, oh well, you can lead a horse to a water and all that............ News on a deal on wearables and this doubles IMHO. I think its going to be that big. Looks like a licensing out deal with recurring revenue, total transparency in revenue streams, from the biggest players on the planet, that are awash with cash. I think the market and investors will love that as we come into an era of great uncertainty. I know it sounds rampy, but with what we already know, talking to 10 majors right now, tell me I am wrong. They approached us remember.
m5
24/11/2020
10:50
Hi all, A bit more about where Elaine's a NED hxxps://www.ipgroupplc.com/ IPO goals in ORPH's space : .."3.3 By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases 3.4 By 2030, reduce by one third premature mortality from non-communicable diseases and promote mental health and well being 3.D Strengthen the capacity for early warning, risk reduction and management of national and global health risks. That network effect, again... ATB
extrader
24/11/2020
10:26
Hopefully a wearables contract before Xmas. Elaine Sullivan will replace the departing Mark Warne as an independent member of the board. Currently chief executive Curadh Pharmaceuticals, she brings with her big company experience, having held senior R&D posts at Lilly and AstraZeneca, as well as an “in-depth background and knowledge” of virology. The latter in particular will be helpful at Open Orphan, which is cementing its place as the world leader in the testing of vaccines and antivirals using human challenge clinical trials. “[Elaine’;s] level of expertise in virology alongside her exceptional career in the industry will be an excellent addition to the company,” said chairman Cathal Friel in a statement.
malcolmmm
24/11/2020
10:25
Laz, Fully agree on eme, I have not as many as a number of shareholders but 1 Million would be near for my holding. I bought in here 10 days ago and will look to add more if BPC or eme increase.
stewart4990
Chat Pages: Latest  404  403  402  401  400  399  398  397  396  395  394  393  Older
ADVFN Advertorial
Your Recent History
LSE
ORPH
Open Orpha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 15:30:43